[溴隐亭对男性泌乳素瘤的治疗作用及其对性功能的影响]

[Effects of bromocriptine on the treatment of prolactinomas in male patients and its influences on their sexual function].

作者信息

Xue Xin-Cheng, Jiang Shu, Yin Sen-Lin, Zhong Chuan-Hong, Zhou Pei-Zhi, Cheng Shu-Wen

机构信息

Department of Neurosurgery, West China Hospital, Sichuan University, Chengdu 610041, China.

出版信息

Sichuan Da Xue Xue Bao Yi Xue Ban. 2013 May;44(3):452-7.

PMID:23898534

Abstract

OBJECTIVE

To explore the effect of bromocriptine in the treatment of male patients with prolactinoma and its impacts on their sexual function.

METHODS

The clinical data of 29 male patients with prolactinomas treated with Bromocriptine were analysed, International Index of Erectile Function-5 (IIEF-5) was used to assess the sexual function of married patients before and after the treatment of Bromocriptine.

RESULTS

The main clinical symptoms of male patients with prolactinomas were sexual dysfunction, headache and hypopsia, which were released significantly at 6 months after Bromocriptine therapy, with the decrease of serum prolactin (PRL) level (P < 0.05) and the improvement of basal testosterone (T) level (P < 0.05). The total normalization rate of PRL was 82.8%, and total effective rate of Bromocriptine therapy was 100%. According to the assessment of IIEF-5, all the male patients had their sexual function improved in various degree.

CONCLUSION

Bromocriptine can improve the clinical symptoms of male patients with prolactinoma and their sexual function.

摘要

目的

探讨溴隐亭治疗男性泌乳素瘤患者的疗效及其对患者性功能的影响。

方法

分析29例接受溴隐亭治疗的男性泌乳素瘤患者的临床资料，采用国际勃起功能指数-5（IIEF-5）评估已婚患者在溴隐亭治疗前后的性功能。

结果

男性泌乳素瘤患者的主要临床症状为性功能障碍、头痛和视力减退，溴隐亭治疗6个月后这些症状明显缓解，血清泌乳素（PRL）水平降低（P<0.05），基础睾酮（T）水平改善（P<0.05）。PRL总正常化率为82.8%，溴隐亭治疗总有效率为100%。根据IIEF-5评估，所有男性患者的性功能均有不同程度改善。